SCHEMBL761997

SCHEMBL761997

CC(C)(C)c1ccc2nccn2c1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 2/20 0.49
KEAP1 Q14145 1/20 0.49
SSTR4 P31391 1/20 0.48
CYP1A2 P05177 2/20 0.46
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
TNKS O95271 1/20 0.43
MCHR1 Q99705 1/20 0.43
TGFBR1 P36897 5/20 0.39
SCN10A Q9Y5Y9 1/20 0.38
PIK3CG P48736 1/20 0.38
RET P07949 1/20 0.38
METAP2 P50579 1/20 0.37
TGFBR2 P37173 1/20 0.36
KIF11 P52732 1/20 0.35
PDE4A P27815 1/20 0.35
PDE3A Q14432 1/20 0.35
GRM2 Q14416 1/20 0.35
MAOB P27338 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19465707 0.85 SSTR4 (0.46) DYRK1AKEAP1SSTR4CYP1A2MEN1
SCHEMBL16252867 0.85 KEAP1 (0.50) DYRK1AKEAP1SSTR4CYP1A2MEN1
SCHEMBL19950935 0.85 SSTR4 (0.49) DYRK1AKEAP1SSTR4CYP1A2MEN1
SCHEMBL22166710 0.85 SSTR4 (0.46) DYRK1AKEAP1SSTR4CYP1A2MEN1
SCHEMBL27904850 0.82 MCHR1 (0.48) DYRK1AKEAP1SSTR4CYP1A2MEN1
SCHEMBL22166769 0.82 SSTR4 (0.44) DYRK1AKEAP1SSTR4CYP1A2MEN1
SCHEMBL18687142 0.82 KEAP1 (0.47) DYRK1AKEAP1SSTR4CYP1A2MEN1
SCHEMBL20132528 0.82 KEAP1 (0.47) DYRK1AKEAP1SSTR4CYP1A2MEN1
SCHEMBL3034110 0.81 MCHR1 (0.56) DYRK1AKEAP1SSTR4CYP1A2MEN1
SCHEMBL24231582 0.80 MCHR1 (0.46) DYRK1AKEAP1SSTR4CYP1A2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 293 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-11 US disclosed
US-20240228478-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2024-07-11 US disclosed
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME ARBUTUS BIOPHARMA CORPORATION (CA) 2024-07-11 US disclosed
US-12030853-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2024-07-09 US disclosed
US-12030853-B2 MASP-2 inhibitors and methods of use OMEROS CORPORATION (US) 2024-07-09 US disclosed
US-20240067641-A1 INHIBITORS OF TRIM33 AND METHODS OF USE DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-02-29 US disclosed
US-20240067641-A1 INHIBITORS OF TRIM33 AND METHODS OF USE DANA-FARBER CANCER INSTITUTE, INC. (US) 2024-02-29 US disclosed
US-20240025849-A1 INHIBITORS OF NO PRODUCTION CHARITÉ - UNIVERSITÄTSMEDIZIN BERLIN (DE) 2024-01-25 US disclosed
US-20240016953-A1 TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS SEAGEN INC (US) 2024-01-18 US disclosed
US-20240016953-A1 TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS SEAGEN INC (US) 2024-01-18 US disclosed
US-20090318436-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-12-24 US disclosed
US-20090318407-A1 Inhibitors of protein kinases PORTOLA PHARMACEUTICALS, INC. (US) 2009-12-24 US disclosed
US-20090258864-A1 PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES RIGEL PHARMACEUTICALS, INC. (US) 2009-10-15 US disclosed
US-20090258864-A1 PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES RIGEL PHARMACEUTICALS, INC. (US) 2009-10-15 US disclosed
US-20090124612-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-05-14 US disclosed
US-20090124609-A1 Fused heterocyclic derivatives and methods of use AMGEN INC. (US) 2009-05-14 US disclosed
US-20090023730-A1 SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION ACHILLION PHARMACEUTICALS (US) 2009-01-22 US disclosed
US-20080176896-A1 Modulators of cellular adhesion BAUSCH + LOMB IRELAND LIMITED (IE) 2008-07-24 US disclosed
US-7365068-B2 Substituted aryl acylthioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. (US) 2008-04-29 US disclosed
US-20060025416-A1 Substituted aryl acylthioureas and related compounds; inhibitors of viral replication ACHILLION PHARMACEUTICALS, INC. 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090318407-A1 Inhibitors of protein kinases SYK, BTK, JAK1 DYRK1A 362/4885KEAP1 2632/4885SSTR4 4064/4885
US-20090318436-A1 Fused heterocyclic derivatives and methods of use HGF, HGFAC, MET DYRK1A 4826/4885KEAP1 417/4885SSTR4 2403/4885
US-20240016953-A1 TARGETED DELIVERY OF NICOTINAMINDE ADENINE DINUCLEOTIDE SALVAGE PATHWAY INHIBITORS NAMPT, NAPRT, NNMT DYRK1A 4550/4885KEAP1 585/4885SSTR4 4353/4885
US-20080176896-A1 Modulators of cellular adhesion ITGB1, VCAM1, ITGB8 DYRK1A 4212/4885KEAP1 2210/4885SSTR4 3719/4885
US-20090124612-A1 Fused heterocyclic derivatives and methods of use HGF, HGFAC, MET DYRK1A 4826/4885KEAP1 417/4885SSTR4 2403/4885
US-20060025416-A1 Substituted aryl acylthioureas and related compounds; inhibitors of viral replication PIGS, NAT1, AADAC DYRK1A 4309/4885KEAP1 619/4885SSTR4 3280/4885
US-20240025849-A1 INHIBITORS OF NO PRODUCTION NOS2, NOS1, NOS3 DYRK1A 4553/4885KEAP1 258/4885SSTR4 3058/4885
US-20240228504-A1 SUBSTITUTED TRICYCLIC AMIDES, ANALOGUES THEREOF, AND METHODS USING SAME SLC10A1, NR1H4, SLC10A2 DYRK1A 1737/4885KEAP1 4113/4885SSTR4 305/4885
US-20240067641-A1 INHIBITORS OF TRIM33 AND METHODS OF USE TRIM33, TRIM28, TRIM4 DYRK1A 3326/4885KEAP1 2720/4885SSTR4 4883/4885
US-20240228478-A1 COMPOUNDS AND METHODS OF USE F12, C1R, ABCG2 DYRK1A 4663/4885KEAP1 1708/4885SSTR4 864/4885
US-20090023730-A1 SUBSTITUTED ARYL ACYLTHIOUREAS AND RELATED COMPOUNDS; INHIBITORS OF VIRAL REPLICATION PIGS, NAT1, AADAC DYRK1A 4309/4885KEAP1 619/4885SSTR4 3280/4885
US-20090258864-A1 PYRIMIDINE-2-AMINE COMPOUNDS AND THEIR USE AS INHIBITORS OF JAK KINASES JAK2, JAK1, JAK3 DYRK1A 137/4885KEAP1 2716/4885SSTR4 2682/4885
US-20090124609-A1 Fused heterocyclic derivatives and methods of use HGF, HGFAC, MET DYRK1A 4826/4885KEAP1 417/4885SSTR4 2403/4885
US-12030853-B2 MASP-2 inhibitors and methods of use MASP2, METAP2, SPINT2 DYRK1A 3476/4885KEAP1 1968/4885SSTR4 3206/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.